(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

M.G.E.H. Lam; T.B. Bosma; P.P. van Rijk; B.A. Zonnenberg

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

Translated title of the contribution: (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

M.G.E.H. Lam
, T.B. Bosma
, P.P. van Rijk
, B.A. Zonnenberg

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Original language	Undefined/Unknown
Pages (from-to)	1425-1433
Number of pages	8
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	36
Issue number	9
Publication status	Published - 2009

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/19319526

Cite this

@article{cede994479f24cbb894fab83890e0f5c,

title = "(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.",

author = "M.G.E.H. Lam and T.B. Bosma and \{van Rijk\}, P.P. and B.A. Zonnenberg",

year = "2009",

language = "Undefined/Unknown",

volume = "36",

pages = "1425--1433",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "9",

}

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. / Lam, M.G.E.H.; Bosma, T.B.; van Rijk, P.P. et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 9, 2009, p. 1425-1433.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.

AU - Lam, M.G.E.H.

AU - Bosma, T.B.

AU - van Rijk, P.P.

AU - Zonnenberg, B.A.

PY - 2009

Y1 - 2009

M3 - Article

SN - 1619-7070

VL - 36

SP - 1425

EP - 1433

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 9

ER -